NEW YORK – The Alzheimer's Drug Discovery Foundation on Wednesday announced that it has invested $7.0 million in Alzheimer's disease diagnostic company C2N Diagnostics. Already have a 360Dx or ...

Trinity plans to bring to market in 2025 Metabolomics Diagnostics' PrePsia test that can be used to determine preeclampsia risk in the 12th week of pregnancy.

Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space ...

The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.

The tool uses two blood-based biomarkers and up to five clinical features to generate a risk score for prostate cancer aggressiveness.

The agreement includes $650 million of 4.35 percent senior notes, $500 million of 4.55 percent senior notes, and $850 million of 4.8 percent senior notes.

The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.

NEW YORK – Fujirebio said Wednesday that its subsidiary Fujirebio Diagnostics has filed its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic with the US Food and Drug ...

Several firms are bringing high-sensitivity cardiac troponin testing into the ER, although doctors are not yet certain how ...

The Baltimore-based subsidiary of Japan's Sysmex said that the test is used to identify genetic mutations that are relevant for the treatment of various cancer types.

The letter encourages drug developers to "further study and use" αSyn-SAA testing for selecting patients for clinical trials for Parkinson's and related diseases.

NEW YORK – A group of researchers from the University of North Carolina, Chapel Hill have validated an array-based assay for subtyping pancreatic cancer that they believe may help determine which ...